The Future of COVID-19 Vaccines

The company raised its full year revenue guidance to $6 billion to $8 billion for the year from $5 billion before. Pfizer CEO Albert Burla said earlier this week that if COVID revenues dissipate more rapidly than they thought, they may consider cost cuts. For Moderna, it's even more vital in that this is their only approved product.